DataVXACS Applied Nano MaterialsPaper
journal article·2024-02-09

Near-Infrared Titania Nanoparticle-Based Photoimmunotherapy via Tumor-Microenvironment-Responsive Gene Editing of SerpinB9 for Triple-Negative Breast Cancer

Kaiyong Yang, Zhenyu Zhang, Chunli Zhang, Qiqing Huang, Zeyu Wang, Gaoyu Shi, Jing Qian, Yanni Song, Yujun Song, Xin Han

ACS Applied Nano Materials· Volume 7· Issue 3
Publisher page
Source abstract

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease with multiple biological subtypes, offering poor clinical outcomes. No targeted therapy was approved for TNBC due to lack of tumor-specific targets. Here, we identify SerpinB9 as a vulnerability target for immunomodulatory TNBC tumors, suggesting that gene editing of SerpinB9 via the CRISPR/Cas9 system may be a viable approach to immunomodulatory TNBC-targeted therapy. To increase bioavailability and improve the delivery efficiency of gene editing, we designed glutathione-responsive nanoparticles to deliver Cas9 ribonucleoprotein targeting SerpinB9 (TiO 2– x @Cas9-RNP@HA). Under near-infrared light irradiation, TiO 2 –x can produce both photodynamic therapy (PDT) and photothermal therapy (PTT) effects. PTT can induce tumor cell ablation and immunogenic cell death. PDT can produce ROS to induce cell killing and downregulation of SerpinB9. Inhibition of SerpinB9 expression with nanoparticles (TiO 2 –x @Cas9-RNP@HA) combined with near-infrared titania phototherapy can synergistically inhibit tumor growth. These results demonstrate the potential of near-infrared titania nanoparticle-based phototherapy and precise SerpinB9-targeted therapies in immunomodulatory TNBCs.
Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Second Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine, Nanjing University of Chinese Medicine, Nanjing210023, China

Department of Breast Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin150081, China

College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing 210023, China

Funding

Natural Science Foundation of Jiangsu Province · Natural Science Foundation of Heilongjiang Province · Harbin Medical University Cancer Hospital · Heilongjiang Provincial Postdoctoral Science Foundation · Chunhui Project Foundation of the Education Department of China · Priority Academic Program Development of Jiangsu Higher Education Institutions · Jiangsu Key Discipline Construction Fund of the 14th Five-Year Plan · Beijing MDK Public Welfare Foundation

References (38)

Show source-provided references
1. 10.1038/s41416-023-02215-z10.1038/s41416-023-02215-z ↗
2. 10.1007/s11864-023-01069-010.1007/s11864-023-01069-0 ↗
3. 10.1136/bmj-2022-07167410.1136/bmj-2022-071674 ↗
4. 10.1093/annonc/mdy02410.1093/annonc/mdy024 ↗
5. 10.1186/s13058-020-01296-510.1186/s13058-020-01296-5 ↗
6. 10.1016/S0140-6736(20)32381-310.1016/S0140-6736(20)32381-3 ↗
7. 10.3892/or.2021.814110.3892/or.2021.8141 ↗
8. 10.1080/2162402X.2022.213907410.1080/2162402X.2022.2139074 ↗
9. 10.1021/acsnano.2c1206610.1021/acsnano.2c12066 ↗
10. 10.1016/j.cell.2020.10.04510.1016/j.cell.2020.10.045 ↗
11. 10.1136/jitc-2022-00636410.1136/jitc-2022-006364 ↗
12. 10.1038/s41423-019-0277-210.1038/s41423-019-0277-2 ↗
13. 10.1038/s41467-023-41255-010.1038/s41467-023-41255-0 ↗
14. 10.1038/s41591-018-0136-110.1038/s41591-018-0136-1 ↗
15. 10.7150/thno.5305610.7150/thno.53056 ↗
16. 10.1002/adma.20200345810.1002/adma.202003458 ↗
17. 10.1002/adma.20210141010.1002/adma.202101410 ↗
18. 10.1002/adma.20220979910.1002/adma.202209799 ↗
19. 10.1002/advs.20220173410.1002/advs.202201734 ↗
20. 10.1016/j.apsb.2021.05.03110.1016/j.apsb.2021.05.031 ↗
21. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
22. 10.1016/j.apsb.2021.11.02010.1016/j.apsb.2021.11.020 ↗
23. 10.1016/j.biomaterials.2021.12123310.1016/j.biomaterials.2021.121233 ↗
24. 10.1002/smll.20230191410.1002/smll.202301914 ↗
25. 10.1016/j.jconrel.2023.06.01210.1016/j.jconrel.2023.06.012 ↗
26. 10.1016/j.apsb.2021.08.01210.1016/j.apsb.2021.08.012 ↗
27. 10.1016/j.apsb.2022.03.01010.1016/j.apsb.2022.03.010 ↗
28. 10.1016/j.biomaterials.2016.01.00910.1016/j.biomaterials.2016.01.009 ↗
29. 10.1002/advs.20230019510.1002/advs.202300195 ↗
30. 10.1039/D2BM02169B10.1039/D2BM02169B ↗
31. 10.1038/s41467-020-17029-310.1038/s41467-020-17029-3 ↗
32. 10.7150/thno.4700710.7150/thno.47007 ↗
33. 10.1016/j.apsb.2022.06.01610.1016/j.apsb.2022.06.016 ↗
34. 10.1126/sciadv.ade539310.1126/sciadv.ade5393 ↗
35. 10.1111/bph.1479310.1111/bph.14793 ↗
36. 10.1016/j.biomaterials.2022.12172310.1016/j.biomaterials.2022.121723 ↗
37. 10.1074/jbc.M115.69929810.1074/jbc.M115.699298 ↗
38. 10.1002/advs.20230133910.1002/advs.202301339 ↗